1Stratton IM,Adler AI,Neil HA,et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS35):prospective observational study.BMJ,2000,321:405-412.
4UK Prospective Diabetes Study Group.Intensive bloodglucose control with Sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33).Lancet,1998,352:837-853.
4The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Report of the expert committee on the diagnosis and Classification of Diabetes Mellitus[J]. Diabetes Care,1997,20:1183-1197
5Pickup JC, Crouk MA. Is type 2 diabets Mellitus a disease of the innate immue system? Diabetologia 1998;41 : 1241 - 1248.
6Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system : association of acute phase reactants and interleukin - 6 with metabolic syndrome X. Diabetologia 1997;40:1286 - 1292.
7Freeman DJ, Norrie J, Caslake MJ, et al. C - reactive protein is an independent predietor of risk for the development of diabetes in the west of Scotland oronary Prevention Study. Diabetes 2002 ; 51 : 1131- 1137.
8Andreas F, Ralph D A, Russell P T, et al. Elevated levels of acute phase proteins and plasminogen aetiveator inhibitor- 1 predict the development of type 2 diabetes: The Insulin Resistance Atherosclerosis Study[J]. Diabetes 2002;51 : 1131 - 1137.
9CaliskanS. Hacibekiroglu M, Sever L et. al. Urinary N - acely -beta - D - glueosaminidase and beta 2 - microglobulin excretion in primary nephrotic children. Nephron 1996;74(2) :401 - 404.
10Dandona P, Aljada A, Mohanty P, et. al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti - inflammatory effect? J Clin Endocrinol Metab 2001;8613257- 3265.
2UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [J]. Lancet, 1998,352(9131 ) : 837-853.
3Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a muhicentre randomised parallel-group trial [J]. Lancet, 2008,371 (9626) : 1753-1760.
6UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration [J]. Diabetologia, 2007,50(6) : 1140-1147.
7Cryer P E. The barrier of hypoglycemia in diabetes [J]. Diabetes, 2008,57(12) : 3169-3176.
